|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Course Drop-out Prediction on MOOC Platform via Clustering and Tensor Completion显示文摘As a supplement to traditional education, online courses offer people, regardless of their age, gender, or profession, the chance to access state-of-the-art knowledge. Nonetheless, despite the large number of students who choose to begin online courses, it is easy to observe that quite a few of them drop out in the middle, and information on this is vital for course organizers to improve their curriculum outlines. In this work, in order to make a precise prediction of the drop-out rate, we propose a combined method MOOP, which consists of a global tensor and local tensor to express all available feature aspects. Specifically, the global tensor structure is proposed to model the data of the online courses, while a local tensor is clustered to capture the inner connection of courses. Consequently, drop-out prediction is achieved by adopting a high-accuracy low-rank tensor completion method, equipped with a pigeon-inspired algorithm to optimize the parameters. The proposed method is empirically evaluated on real-world Massive Open Online Courses(MOOC) data, and is demonstrated to offer remarkable superiority over alternatives in terms of efficiency and accuracy. | Jinzhi Liao Jiuyang Tang Xiang Zhao | 2019 | Tsinghua Science and Technology2019，24，4： | 5 |
| 2 | Extranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options显示文摘Objective: Extranodal involvement represents a peculiar presentation of diffuse large B-cell lymphoma(DLBCL). Previous studies have suggested that older patients are more prone to extranodal involvement. This study retrospectively addressed the distribution, prognostic value and treatment options of extranodal involvement in young patients with DLBCL.Methods: A total of 329 patients were enrolled according to the inclusion requirements. The effects of gender,extranodal involvement, age-adjusted international prognostic index(aa IPI), rituximab infusion and radiotherapy on patient outcomes were evaluated.Results: Among these patients, 59% presented extranodal involvement in 16 anatomic sites. More than one instance was linked to many poorer clinical characteristics and poorer survival compared with either nodal disease or one instance. In patients with one extranodal lesion, multivariate analysis revealed that the site of extranodal involvement, but not the aa IPI or rituximab infusion, was independently related to the outcome, and radiotherapy had a negative influence on survival.Conclusions: Extranodal involvement is common in younger patients and exhibits a ubiquitous distribution.The site of extranodal involvement is of strong prognostic significance. Radiotherapy for extranodal lesions does not improve patient outcomes. | Shuna Yao Junbo Li Zhihua Yao Yuanlin Xu Junfeng Chu Jiuyang Zhang Shuiling Jin Yangyang Huang Jianbo Zhang Jie Ma Yan Zhao Shujun Yang Yanyan Liu | 2017 | Chinese Journal of Cancer Research2017，29，1： | 3 |
| 3 | Proteomic study provides new clues for complications of hemodialysis caused by dialysis membrane显示文摘The complications of hemodialysis accompanied the hemodialysis and threaten the patients’life.Besides the loss of nutrient substance,such as amino acid and vitamin,we found new clues that the adsorbed proteins on common-used polysulfone-based dialysis membrane might be the reason according to the qualitative proteomic study by ionic liquid assisted sample preparation method.Our results indicated that the adsorbed proteins on the membrane were related with complement activation,blood coagulation,and leukocyte-related biological process.The quantitative proteome further demonstrated some significant changes of signal proteins in the post-dialysis plasma after the hemodialysis,such as beta-2-microglobulin and platelet factor-4,which would further verify these new clues. | Kaiguang Yang Jianhui Liu Jingdi Sun Yuan Zhou Qun Zhao Senwu Li Lukuan Liu Lihua Zhang Jiuyang Zhao Yukui Zhang | 2017 | Science Bulletin2017，62，18： | 2 |
| 4 | Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients:A randomized,open-label,parallel-group,noninferiority phase III trial显示文摘Background:This study was to explore the clinical efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection(recombinant human erythropoietin injection,rHuEPO)for the treatment of anemia associated with chronic kidney failure in Chinese patients undergoing hemodialysis.Method:This study was a multicenter,randomized,open-label,intergroup parallel control phase III noninferiority trial from April 19,2013 to September 9,2014 at 25 sites.In this study,the members of the darbepoetin alfa group underwent intravenous administration once per week or once every two weeks.The members of the control drug epoetin alfa group underwent intravenous administration two or three times per week.All subjects underwent epoetin alfa administration during the 8-week baseline period.After that,subjects were randomly assigned to the darbepoetin alfa group or epoetin alfa group.The noninferiority in the changes of the average Hb concentrations from the baseline to the end of the evaluation period(noninferiority threshold:-1.0 g/dl)was tested between the two treatments.The time-dependent hemoglobin(Hb)concentration and the maintenance rate of the target Hb concentration(the proportion of subjects with Hb concentrations between 10.0 and 12.0 g/dl)were also evaluated.Iron metabolism,including changes in the serum iron,total iron-binding capacity,ferritin,transferrin saturation,and comparisons of the dose adjustments between the two groups during the treatment period were analyzed further.Adverse events(AEs)were also observed and compared,and the safety was analyzed between the two treatment groups.The conversion rate switching from epoetin alfa to darbepoetin alfa was also discussed.SAS?software version 9.2 was used to perform all statistical analyses.Descriptive statistics were used for all efficacy,safety,and demographic variable analyses,including for the primary efficacy indicators.Results:Four hundred and sixty-six patients were enrolled in this study,and ultimately 384 cases were analyzed for safety,including 267 cases in the darbepoetin alfa group and 117 cases in the epoetin alfa group.There were 211 cases in the per-protocol set,including 152 cases in the darbepoetin alfa group and 59 cases in the epoetin alfa group.The changes in the average Hb concentrations from the baseline to the end of the evaluation period were-0.07 and-0.15 g/dl in the darbepoetin alfa group and epoetin alfa group respectively.The difference between the two groups was 0.08 g/dl(95%confidence interval[CI]:-0.22 to 0.39),and the lower limit of the 95%CI was-0.22>-1.0 g/dl.The average Hb concentrations of the two groups were 10.88-11.43 g/dl(darbepoetin alfa)and 10.91-11.38 g/dl(epoetin alfa)during the study period of Weeks 0-28,with the maintenance rates of the target Hb concentration ranging within 71%-87%and 78%-95%in the darbepoetin alfa group and epoetin alfa group respectively.During the period of comparison between the two groups,the incidence of AEs in the darbepoetin alfa group was 61.42%,while in the epoetin alfa group it was 56.41%.All of the adverse events and reactions in the study were those commonly associated with hemodialysis.Conclusion:The overall efficacy and safety of darbepoetin alfa for the treatment of Chinese renal anemia patients undergoing hemodialysis are consistent with those of epoetin alfa. | Bicheng Liu Nan Chen Jinghong Zhao Aiping Yin Xiongfei Wu Changying Xing Gengru Jiang Junzhou Fu Mei Wang Rong Wang Jianying Niu Ping Fu Zhaohui Ni Fanfan Hou Jiuyang Zhao Jing Chen Yuqing Chen Wei Shi Jianghua Chen Wenge Li Gang Xu Ling Zhong Wenhu Liu Guohua Ding Yuichiro Kondo Changhe Yue Changlin Mei | 2022 | Chronic Diseases and Translational Medicine2022，8，2： | 1 |
| 5 | Omniphobic membranes for distillation:Opportunities and challenges显示文摘As an emerging thermal-driven membrane technology,membrane distillation(MD)has attracted immense attention for desalination and water purification.The membranes for MD generally have hydrophobic or superhydrophobic properties to enable vapor permeation without liquid passage(e.g.,wetting).However,conventional MD membranes cannot undergo long term stable operations due to gradual wetting in practical applications where the feed solution often contains multiple low-surface tension contaminants(e.g.,oil).Recently,omniphobic membranes repelling all sorts of liquids and typically having ultralow surface energy and re-entrant structures have been developed for robust MD to mitigate wetting and fouling.In this paper,we aim to provide a comprehensive review of recent progress on omniphobic membranes.Fundamentals,desirable properties,advantages and applications of omniphobic membranes are discussed.We also summarize the research efforts and methods to engineer omniphobic membranes.Finally,the challenges and future research directions on omniphobic membranes are discussed. | Tianlong Ni Jiuyang Lin Lingxue Kong Shuaifei Zhao | 2021 | Chinese Chemical Letters2021，32，11： | 1 |
| 6 | Study on Metal Flow in Cable Aluminum Sheath Continuous Extrusion Cladding Using FEM Analysis 显示文摘 | Zhao Ying Song Baoyun Pei Jiuyang | 2011 | Advanced Materials Research2011，，189193： | 1 |
| 7 | Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure:A randomized,open-label,parallel-group,non-inferiority Phase III trail显示文摘Background:Erythropoietin is a glycoprotein that mainly regulates erythropoiesis.In patients with chronic renal failure with anemia,darbepoetin alfa can stimulate erythropoiesis,correct anemia,and maintain hemoglobin levels.This study was designed to demonstrate the efficacy and safety of darbepoetin alfa injections as being not inferior to epoetin alfa injections(Recombinant Human Erythropoietin injection,rHuEPO)when maintaining hemoglobin(Hb)levels within the target range(10.0-12.0 g/dL)for the treatment of renal anemia.Methods:Ninety-five patients were enrolled in this study from April 15,2013 to April 10,2014 at 25 sites.In this study,patients(n=95)aged 18-70 years were randomized into a once per week intravenous darbepoetin alfa group(n=56)and a twice or three times per week intravenous epoetin alfa group(n=39)for 28 weeks,who had anemia with hemoglobin levels between 6 g/dL and 10 g/dL due to chronic kidney disease(CKD)and were undergoing hemodialysis or hemofiltration with ESA-naive(erythropoiesis stimulating agent-naive).The primary efficacy profile was the mean Hb level(the non-inferiority margin was-1.0 g/dL,week 21-28);the secondary efficacy profiles were the Hb increase rate(week 0-4),the target Hb achievement cumulative rate and time,the change trends of the Hb levels,and the target Hb maintenance ratio.Adverse events(AEs)were observed and compared,and the efficacy and safety were analyzed between the two treatment groups.Additionally,the frequencies of dose adjustments between the darbepoetin alfa and epoetin alfa groups were compared during the treatment period.SAS?software version 9.2 was used to perform all statistical analyses.Descriptive statistics were used for all efficacy,safety,and demographic variable analyses,including for the primary efficacy indicators.Results:The mean Hb level was 11.3 g/dL in the darbepoetin alfa group and 10.7 g/dL in the epoetin alfa group,respectively;the difference of the lower limits of the 95%confidence intervals(CI)between the two groups was 0.1 g/dL(>-1.0 g/dL),and non-inferiority was proven;the Hb levels started to increase in the first four weeks at a similar increase rate;no obvious differences were observed between the groups in the target Hb achievement cumulative rates,and the Hb levels as well as the target Hb level maintenance rate changed over time.The incidence of AEs was 62.5%in the darbepoetin alfa group and 76.9%in the epoetin alfa group.All the adverse events observed in the study were those commonly associated with hemodialysis.Conclusion:Darbepoetin alfa intravenously once per week can effectively increase Hb levels and maintain the target Hb levels well,which makes it not inferior to epoetin alfa intravenously twice or three times per week.Darbepoetin alfa shows an efficacy and safety comparable to epoetin alfa for the treatment of renal anemia. | Nan Chen Changying Xing Jianying Niu Bicheng Liu Junzhou Fu Jiuyang Zhao Zhaohui Ni Mei Wang Wenhu Liu Jinghong Zhao Ling Zhong Xiongfei Wu Wenge Li Yuqing Chen Wei Shi Jianghua Chen Aiping Yin Ping Fu Rong Wang Gengru Jiang Fanfan Hou Guohua Ding Jing Chen Gang Xu Yuichiro Kondo Yuliang Su Changlin Mei | 2022 | Chronic Diseases and Translational Medicine2022，8，1： | 1 |
| 8 | Effect of deformation speed on the microstructure and mechanical properties of AA6063 during continuous extrusion process显示文摘 | Ying Zhao Baoyun Song Jiuyang Pei Chunbo Jia Bing Li Guo Linlin | 2013 | Journal of Materials Processing Tech2013，，11： | 1 |
| 9 | Analytical measurement method for situation elements' dynamic characteristics显示文摘This paper gives an analysis of the dynamic characteristics of situation elements(SEs) in situation awareness(SA)research. The purpose of the discussion is to understand the factors that influence SA and to help in designing the training systems to improve operators' SA. The status function of SEs is defined and the derivative of the function represents trends of the status of SEs at each moment. Then, Fourier transform(FT) is used to give the frequency-domain function in terms of the time-domain status function. In frequency domain, the bandwidth of the status function is used as a criterion to characterize the notion of 'fast' and'slow' of the change of SE's status, which represents the dynamic characteristic of SEs. The criterion constitutes the first analytical measurement of the dynamic characteristic of SEs, which is one of the important factors that influence the SA process. | Huiyun Zhao Dongge Zhang Hui Meng Jiuyang Tao | 2017 | Journal of Systems Engineering and Electronics2017，28，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员